Biotia, a NYC-based health tech company, raised $2.4M in seed funding.
The round was led by Falcon III Ventures, with participation from angel investors and venture capital firms including Hyperplane Venture Capital.
The company intends to use the funds to further develop and implement its diagnostic testing methods, including its AI-based software Chelsea™.
Led by Dr. Niamh B. O’Hara (Co-Founder, and CEO), Dr. Christopher E. Mason (Co-Founder, Global Director, and Associate Professor at Weill Cornell Medicine), Dr. Rachid Ounit (Co-Founder, and CTO) and Dr. Dorottya Nagy-Szakal (Chief Medical Officer), Biotia leverages next-generation DNA sequencing (NGS) and artificial intelligence (AI) software for precision infectious disease detection and diagnosis. The company’s AI-based software, Chelsea™, can identify known and emerging bacteria, fungi, parasites and viruses from a clinically-curated and annotated database of over 16,000 microbial species, as well as antimicrobial resistance (AMR) genetic markers and virulence genetic markers.
Chelsea’s engine offers a “precision metagenomic” test, including a complete report of the microbial profile and predicted drug resistance. The company expects this test will provide the guidance needed by clinicians to provide effective patient treatment and will help hospitals reduce the number of hospital-acquired infections (HAIs).
Biotia plans to launch new CAP/CLIA clinical diagnostic tests in early 2020.